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Background: Right heart catheterization remains the gold standard in diagnosis and evaluation of pulmonary arterial hypertension (PAH). The aim 
of this study was to verify whether changes in hemodynamics reflect the incidence of clinical events in PAH patients.
Methods: MEDLINE, Cochrane, ISI Web of Science and SCOPUS database were searched for articles about PAH treatment until November 2011. All 
randomized trials assessing hemodynamics at baseline and at end of follow-up and including clinical end-points (all-cause death, hospitalization for 
PAH and/or lung or heart-lung transplantation, initiation of PAH rescue therapy) were included. Meta-analysis was performed to assess the influence 
of treatments on outcomes. Meta-regression analysis was performed to test the relationship between hemodynamics (pulmonary artery pressure, 
pulmonary vascular resistance, cardiac index and right atrial pressure) changes and outcomes. The influence of baseline patients’ characteristics, 
hemodynamics at baseline, 6-minute walk distance (6MWD), Detsky quality score, follow-up and study publication year were also explored. 
Macaskill’s modified test was used to assess the presence of publication bias.
Results: 17 trials enrolling 2,417 participants were included. Active treatments led to significant reduction in the risk of all-cause death (odds 
ratio [OR]: 0.533; 95% confidence interval [CI]: 0.341 to 0.833; p<0.01), hospitalization for PAH and/or lung or heart-lung transplantation (OR: 
0.384; CI: 0.218 to 0.674; p<0.01), initiation of PAH rescue therapy (OR: 0.341; CI: 0.200 to 0.582; p<0.01) and composite outcome (OR: 0.368; 
CI: 0.277 to 0.489; p<0.01). In meta-regression analysis, no relationship between hemodynamics changes from baseline to end of follow-up and 
outcomes was detected. No potential confounding variable or publication bias was detected. There was no heterogeneity among trials included in 
meta-analysis. Changes in pulmonary vascular resistance correlated with changes in 6MWD (r=-0.63; p<0.01).
Conclusions: in PAH patients, improvement in pulmonary hemodynamics, induced by pharmacological treatment, does not predict reduction in 
clinical outcomes.
